ACELYRIN, INC. (SLRN) AI Stock Analysis

• Market Cap: $244.20M
• Dividend Yield: N/A
• Average Volume (3M): 893.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.08
• Revenue Growth: N/A
• EPS Growth: 36.27%
• Country: US
• Employees: 83
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -1.03
• Shares Outstanding: 100,907,200
• 10 Day Avg. Volume: 753,734
• 30 Day Avg. Volume: 893,757
• PEG Ratio: -0.15
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $20.00
• Price Target Upside: 747.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

SLRN faces significant financial challenges with no current revenue generation and reliance on external financing. However, the announced merger with Alumis Inc. is a positive strategic development that may improve future prospects. Technical indicators are mixed, and the company's valuation metrics are unattractive due to ongoing losses. Investors should be cautious, considering the high risk associated with the company's current financial situation.

Positive Factors

Efficacy Potential

The Ph3 regimen of 100mg LD + 50mg Q2W could potentially increase drug exposure, possibly boosting its efficacy.

Regimen Flexibility

All patients will be able to receive lonigutamab after 24 weeks through 52 weeks of treatment, allowing for potentially longer-term treatment compared to fixed dose regimens.

Safety Profile

Lonigutamab's safety profile looks promising versus competitors, with no hearing impairment, no hyperglycemia, and no elevation of circulating IGF1.

Negative Factors

Dosing Concerns

Concerns exist on a more frequent dosing interval for lonigutamab versus subQ competition.

Efficacy Uncertainty

Shares are weak post the disclosure on the selection of Q2W for the Ph3 dosing regimen and uncertainty surrounding efficacy expectations for a Ph3 dose not tested in the Ph1b/2 study.

Trial Outcome

Acelyrin recently announced that the PhII/III study evaluating izokibep in uveitis did not meet the trial's primary endpoint of time to treatment failure.

ACELYRIN, INC. Business Overview & Revenue Model

Company Description

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

How the Company Makes Money

ACELYRIN, INC. generates revenue primarily through the commercialization of its pharmaceutical products. The company's revenue model is centered around the successful development and sale of its drug candidates. This includes income from product sales once a drug is approved by regulatory bodies and launched in the market. Additionally, ACELYRIN may enter into strategic partnerships and collaborations with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on product sales. These partnerships can significantly contribute to the company's earnings by expanding its reach and accelerating the development and distribution of its therapies.

ACELYRIN, INC. Financial Statement Overview

Summary

ACELYRIN, INC. faces significant financial challenges with no revenue and substantial net losses, typical for early-stage biotech firms. The strong cash position provides a buffer, but reliance on external financing poses risks if product development does not progress as planned.

Income Statement

The company has consistently reported zero revenue over the years, indicating a lack of commercialized products or services. The net losses are substantial, with no gross or net profit margins, highlighting ongoing operational challenges without revenue generation.

Balance Sheet

The company has a strong cash position relative to its debt, with a low debt-to-equity ratio due to minimal debt levels. However, negative stockholders' equity in earlier years indicates financial instability and potential risk to investors, though recent improvements are noted.

Cash Flow

Negative free cash flow indicates that the company is consuming cash, likely due to its development stage without revenue. Operating cash flows are negative, reflecting high R&D or operational expenses. The reliance on financing activities to support cash needs highlights the potential risk of dilution or debt increases.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
0.00	-115.00K	0.00	0.00
	EBIT
-316.26M	-422.06M	-254.68M	-41.79M
	EBITDA
-316.26M	-381.53M	-64.77M	-41.84M
	Net Income Common Stockholders
-248.23M	-381.64M	-250.46M	-41.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
447.88M	721.33M	326.07M	102.24M
	Total Assets
491.14M	742.69M	332.96M	102.30M
	Total Debt
6.27M	1.19M	0.00	0.00
	Net Debt
-67.62M	-216.90M	-278.56M	-102.24M
	Total Liabilities
32.85M	86.35M	444.35M	144.36M
	Stockholders Equity
458.29M	656.34M	-111.39M	-42.06M
Cash Flow		Free Cash Flow
-305.17M	-182.00M	-61.52M	-29.98M
	Operating Cash Flow
-303.92M	-169.71M	-61.52M	-4.98M
	Investing Cash Flow
154.87M	-447.74M	-47.87M	-25.00M
	Financing Cash Flow
5.39M	568.44M	274.26M	124.72M

ACELYRIN, INC. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLRN, the sentiment is Negative. The current price of 2.36 is above the 20-day moving average (MA) of 2.34, below the 50-day MA of 2.48, and below the 200-day MA of 3.79, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 47.94 is Neutral, neither overbought nor oversold. The STOCH value of 53.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLRN.

ACELYRIN, INC. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$243.38M	―	-41.31%	―	―	-7.93%
Sector *	52 Neutral	$5.15B	3.56	-42.52%	2.83%	14.56%	-0.53%
AVIR	47 Neutral	$239.47M	―	-33.88%	―	―	-22.66%
ITOS	46 Neutral	$253.37M	―	-23.68%	―	―	14.60%
ATXS	44 Neutral	$246.62M	―	-33.52%	―	―	27.92%
SLRN	40 Underperform	$244.20M	―	-44.54%	―	―	36.27%
CADL	33 Underperform	$236.99M	―	-139.56%	―	―	-33.79%

ACELYRIN, INC. Corporate Events

ACELYRIN, INC. Amends Merger Agreement with Alumis

On February 6, 2025, ACELYRIN, INC. entered into a merger agreement with Alumis Inc., which was later amended on April 20, 2025. The merger will result in ACELYRIN becoming a wholly owned subsidiary of Alumis, with Alumis stockholders owning approximately 52% and ACELYRIN stockholders owning about 48% of the combined company’s common stock. The boards of both companies have unanimously recommended the merger as beneficial for their respective stockholders. A special meeting for ACELYRIN stockholders to vote on the merger is scheduled for May 19, 2025.

Spark’s Take on SLRN Stock

According to Spark, TipRanks’ AI Analyst, SLRN is a Underperform.

The overall score reflects significant financial challenges and bearish technical indicators for ACELYRIN, INC. However, the potential merger and strategic pipeline developments provide some optimism. Investors should be cautious, noting the high-risk nature of the company’s financial position and the need for successful product development.

To see Spark’s full report on SLRN stock, click here.

ACELYRIN, INC. Announces Merger with Alumis Inc.

On February 6, 2025, ACELYRIN, INC. and Alumis Inc. announced a definitive merger agreement under which ACELYRIN will become a wholly owned subsidiary of Alumis in an all-stock transaction. The merger, unanimously approved by the boards of both companies, is expected to create a late-stage clinical biopharma company focused on developing and commercializing transformative therapies for immune-mediated diseases. The merged entity will operate under the Alumis name with a pro forma cash position of approximately $737 million, providing financial flexibility for future developments. The transaction is anticipated to close in the second quarter of 2025, subject to customary approvals.